Dr. Paula James MD, FRCPC

 

Departments of Medicine and Pathology
& Molecular Medicine 
Etherington Hall, Room 2025
Queen's University
Kingston, Ontario
K7L 2V6, CANADA
TEL: (613) 533-2946
FAX: (613) 533-6855
e-mail: jamesp (at) queensu.ca


Position

Associate Professor, Department of Medicine, Divison of Hematology
Cross-Appointment, Department of Pathology and Molecular Medicine
Cross-Appointment, Department of Pediatrics

Other Positions

Chair of the Research Advisory Committee of the Canadian Hemophilia Society
Co-Chair of the von Willebrand Factor Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH)

Medical Director of the Inherited Bleeding Disorders Clinic of Southeastern Ontario
Medical Director of the Women and Bleeding Disorders Clinic – Kingston General Hospital
Co-Director National Hemophilia Mutation Detection Program - Responsible for VWD genetic testing
Member of the ISTH SSC von Willebrand Factor Mutation Database Steering Committee

Scholarly Activities

Editorial Board of Haemophilia
Member of Global Emerging Hemophilia Expert Panel (GEHEP) - sponsored by Bayer Inc.

Education

Degree - M.D., University of Saskatchewan

Postgraduate Medical Training
PGY 4 & 5 Hematology, Queen's University
PGY 1 - 3 Internal Medicine, University of Saskatchewan

Postdoctorial Research Training
Fellow
- Clinical Investigator Program of The Royal College of Physicians and Surgeons of Canada - Molecular Hemostasis
- Department of Pathology, Queen's University - Supervisor: Dr. David Lillicrap

Scholarships and Awards

2012 Basmajian Award for Excellence in Health Sciences Research – Queen’s University
2011 Researcher of the Year Award of Excellence – National Hemophilia Foundation
2011 Clinician Scientist Development Program Award – Southeastern Ontario Medical Organization
2008 Aesculapian Society Queen’s Medical School Phase IIA Teaching Award
2008 CSL Behring Prof. Heimburger Award – Early Career Investigator Award
2007 Excellence in Research Award, Department of Medicine Queen’s University
2007 Bayer International Hemophilia Awards – Early Career Investigator Award
2005 Young Investigator Award – International Society of Thrombosis and Hemostasis
2003 John H. Crookston Award – Canadian Hematology Society
2003 Aventis Behring – CHS – AHCDC Fellowship
2002 Aventis Behring – CHS – AHCDC Fellowship
2000 Ian Holmes Senior Professionalism Award, University of Saskatchewan



Research Interests

Our primary research interest is focused on investigating the genotype/phenotype interactions in all subtypes of von Willebrand disease and in Hemophilia. Our projects not only examine the molecular genetic basis of these inherited bleeding disorders, but the impact of these disorders clinically as well. We are also particularly interested in the quantitation of bleeding symptoms and understanding correlations between bleeding scores and the molecular basis of disease. Our program strives to achieve a "bench-to-bedside" perspective; translating our basic science research into clinically useful data.


Dr. Paula James Research Group
Kingston, ON - June 2013



Selected Publications
(Past 5 Years)

Peer- reviewed:

Sim Yan, Bowman M, Hopman W, Engen D, Silva M and James PD.
Predicting Operative Bleeding in Elective Pediatric Surgeries using the Pediatric Bleeding Questionnaire (PBQ).
Accepted by J Ped Hematol Oncol May 2013.

Kahlon A, Grabell J, Tuttle A, Engen D, Hopman W, Lillicrap D and James PD.
Quantitation of Peri-operative Changes in von Willebrand Factor and Factor VIII During Elective Orthopedic and Cardiac Surgery in Normal Individuals.
Haemophilia 2013 [Epub ahead of print] DOI:10.1111/hae.12185.

Rimmer E, Jamieson MA, James PD.
Malposition and Expulsion of the Levonorgestrel Intrauterine System Among Women with Inherited Bleeding Disorders.
Haemophilia 2013 [Epub ahead of print] DOI: 10.1111/hae.12184.

Holden R, Tuttle A, Burbidge T, Hegadorn C, Grabell J and James PD.
Quantitative and qualitative changes of von Willebrand factor and their impact on mortality in patients with end stage kidney disease.
Accepted by Blood, Coagulation & Fibrinolysis, March 2013

Rydz N, Swystun L, Notley C, Paterson A, Riches J, Boonyarat B, Montgomery RR, James PD, Lillicrap D.
The C-type lectin receptor CLEC4M (L-SIGN) binds to, internalizes and contributes to the clearance of von WIllebrand factor and variation in plasma von Willebrand factor levels.
Blood 2013 [Epub ahead of print] PMID:23529928.

Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O’Donnell JS, Federici AB, Lillicrap D, James PD, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jiminez-Yuste V, Lee C.
Third Aland islands conference on von Willebrand disease, 26 – 28 September 2012: meeting report.
Haemophilia. March 19, 2013; Suppl 3:1-18. PMID 23383607.

James PD and Lillicrap D.
The molecular characterization of von Willebrand disease: Good in parts.
Brit J Haem Epub ahead of print, February 14, 2013. PMID 23406206.

Bowman M, Tuttle A, Notley C, Brown C, Tinlin S, Deforest M, Leggo J, Blanchette VS, Lillicrap D, James P for the Association of Hemophilia Clinic Directors of Canada. The Genetics of Canadian Type 3 von WIllebrand Disease (VWD): Further Evidence for Co-dominant Inheritance of Type 3 VWD Alleles.
J Thromb Haemost 2013 Mar; 11(3): 512-20. PMID 23311757

James PD, Kasthuri R, Kruse-Jarres R, Soni A, Kulkarni R, Dolan G. Global Emerging HEmophilia Panel (GEHEP):
A Multinational Collaboration for Advancing Hemophilia Research and Treatment.
Accepted for publication in Transfusion Medicine and Hemotherapy, December 20, 2012.

James PD, Lillicrap DP and Mannucci PM.
Alloantibodies in von Willebrand Disease.
Blood Epub ahead of print, January 7, 2013. PMID 23297130

Rydz N and James PD.
The Evolution and Value of Bleeding Assessment Tools.
J Thromb Haemost 2012: 10: 2223-2229. PMID: 22974079.

Rydz N and James PD.
Approach to the diagnosis and management of common bleeding disorders.
Sem Thromb Haemost 2012; 38: 711-719. PMID: 22941792

James PD and Coller B.
Phenotyping Bleeding.
Current Opinion in Hematology 2012, 19:406-412. PMID: 22759628


James PD
, Lillicrap D. 
von Willebrand Disease:  Clinical and Laboratory Lessons Learned from the Large von Willebrand Disease Studies.
Am J Hematol 2012 Feb 8, doi: 10.1002/ajh.23142 Epub ahead of print PMID: 22389132

Rydz N and James PD. 
Why is my patient bleeding or bruising?
Hematol Oncol Clin N Am 2012 (26); 321-344.

Federici AB, James PD
Current management of patients with severe von Willebrand disease type 3: a 2012 update. 
Accepted by Haematologica, February 2012.

Sanders S, Purcell S, Silva M, Palerme S, James PD
Relationship between diagnosis and intervention in women with inherited bleeding disorders and menorrhagia. 
Haemophilia, 2012 Jan 5, doi: 10.1111/j.1365-2516.2011.02740.x Epub ahead of print PMID: 22221914

Goodeve A, James P.
von WIllebrand Disease (October 2011) in: GeneReviews at GeneTests: Medical Genetics Information Resource.
Available at http://www.genetests.org. PMID: 20301765

Robertson, JD, Yenson PR, Rand ML, Carcao M, Blanchette VS, Lillicrap D, James PD.
Expanded Phenotype-Genotype Correlations in a Pediatric Population with Type 1 von Willebrand Disease.
J Thromb Hamost 2011; 9:1752-1760

James P and Lillicrap D.
The Diagnosis and Management of von Willebrand Disease in Canada.
Semin Thromb Hemost 2011; 37: 522-527

James P and Lillicrap D.
The Diagnosis and Management of von Willebrand Disease in Canada.
Accepted by Seminars in Thrombosis and Haemostasis. January 2011.

James P and Goodeve A.
von Willebrand Disease.
Genetics in Medicine 2011 May; 13(5): 365-376. PMID 21289515

Levac B, Parlow J, vanVlyman J, James P, Tuttle A, Shepherd L.
Ringer’s Lactate is Compatible with SAGM Preserved Packed Red Blood Cells for Rapid Transfusion.
Can J Anaesth 2010; 57(12): 1071- 1077.

Darwish H, Mundell G, Engen D, Lillicrap D, Silva M and James PD.
Early Intraoperative Blood Collection Does Not Affect CBCs, VWF or FVIII Levels in Normal Children.
J Ped Hematol Oncol 2011; 33(1): 47 - 49.

Othman M, Chirinian Y, Brown C, Notley C, Hickson N, Hampshire D, Buckley S, Waddington S, Parker A, Baker A, James P, Lillicrap D.
Functional characterization of a 13 bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease.
Blood 2010; 116: 3645-52.

Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P, Neunert C and Lillicrap D on behalf of the ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group.
ISTH/SSC Bleeding Assessment Tool: A Standardized Questionnaire and a Proposal for a New Bleeding Score for Inherited Bleeding Disorders.
J Thromb Haemost 2010; 8: 2063-5.

James P and DiPaola J.
The Application of Genetics to Inherited Bleeding Disorders.
Haemophilia 2010; 16 (Suppl 5):1-5.

Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici A, James P, Peake I, Eikenboom J, Goodeve A on behalf of EU-VWD and ZPMCB-VWD Study Groups.
Von Willebrand Factor Variant p.Arg924Gln Marks an Allele Associated with Reduced von Willebrand Factor and Factor VIII Levels.
J Thromb Haemost 2010; 8:1986-93.

Biss TT, Blanchette VS, Clark DS, Wakefield C, James PD and Rand ML.
Use of a quantitative Pediatric Bleeding Questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder.
J Thromb Haemost 2010; 8:1416-1419.

Biss TT, Blanchette VS, Clark DS, Bowman M, Wakefield C, Silva M, James PD and Rand ML.
Quantitation of Bleeding Symptoms in Children with von Willebrand Disease (VWD): Use of a Standardized Pediatric Bleeding Questionnaire.
J Thromb Haemost 2010; 8:950-956.

M. Bowman, W.M. Hopman, D. Rapson, D. Lillicrap and P. James.
The Prevalence of Symptomatic VWD in Primary Care Practice.
J Thromb Haemost 2010; 8:213-216.

M. Bowman, W.M. Hopman, D. Rapson, D. Lillicrap, M. Silva, and P. James.
A Prospective Evaluation of the Prevalence of Symptomatic von Willebrand Disease (VWD) in a Pediatric Primary Care Population.
Pediatric Blood & Cancer 2010; 55:171-173.

Mittal N, James P and Valentino L.
Diagnosis of von Willebrand Disease in Children.
Current Pediatric Reviews 2009; 5:169-175.

Berber E, James PD, Hough C, Lillicrap D.
An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.
J Thromb Haemost 2009; 7:1672-79.

Bowman M, Riddel J, Rand M, Tosetto A, Silva M, and James P
.Evaluation of the Diagnostic Utility for von Willebrand Disease of a Pediatric Bleeding Questionnaire.
J Thromb Haemost 2009; 7:1418-21.

Goodeve AC and James P.
Von Willebrand Disease in: GeneReviews at GeneTests: Medical Genetics Information Resource June 2009 (database online).
Copyright, University of Washington, Seattle, 1997-2009. http://www.genetests.org.

Albert K, Van Vlyman J, James P, Parlow J.
Ringer’s Lactate is Compatible with the Rapid Infusion of AS-3 Preserved Packed Red Blood Cells.
Canadian Journal of Anaesthesia 2009; 56:352-356.

Bowman M, Mundell G, Grabell J, Hopman W, Rapson D, Lillicrap D, James P.
Generation and Validation of the Condensed MCMDM1-VWD Bleeding Questionnaire.
J Thromb Haemost 2008; 6: 2062-6.

Rodeghiero F, Kadir R, Tosetto A, James P.
Relevance of quantitative assessments of bleeding in haemorrhagic disorders.
Haemophilia 2008 Jul;14 Suppl 3: 68-75.

James PD, Stakiw J, Leggo J, Walker I, Lillicrap D.
A Case of Non-Resolving Hemophilia B Leyden in a 42 year old Male (F9 promoter +13 A>G).
J Thromb Haemost 2008; 6: 885-6.

Robertson J, Lillicrap D, James P.
von Willebrand Disease.
Pediatr Clin North America. 2008 Apr; 55(2):377-92.

Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting PJ, Lillicrap D, James P.
The Effect of Exercise on VWF and ADAMTS-13 in Individuals with Type 1 and Type 2B VWD.
J Thromb Haemost 2008; 1: 90-6.

James PD, Notley C, Hegadorn C, Poon M-C, Walker I, Rapson D, AHCDC, Lillicrap D.
Challenges in Defining Type 2M von Willebrand Disease: Results from a Canadian Cohort Study.
J Thromb Haemost 2007; 5: 1914-22.

James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O’Brien L, Othman M, Rivard G, Rapson D, Hough C, AHCDC, Lillicrap D.
The Mutational Spectrum of Type 1 von Willebrand Disease: Results from a Canadian Cohort Study.
Blood; Jan 2007; 109(1):145-154.

Chapters/Monographs:

Rydz N and James PD.
von Willebrand Factor and von Willebrand Disease.
Hoffman, Hematology 6e, Elsevier, 2011.

James PD, Tosetto A.
Clinical Aspects of von Willebrand Disease: Bleeding History.
Chapter in von Willebrand Disease: Basic and Clinical Aspects. Wiley-Blackwell 2011.

James PD, Lillicrap D.
Von Willebrand Disease: an Introduction for the Primary Care Physician, Treatment of Hemophilia Monographs.
The World Federation of Hemophilia, January 2009, No. 47.

James PD, Lillicrap D.
The Role of Molecular Genetics in Diagnosing von Willebrand Disease.
Chapter in Seminars in Thrombosis and Hemostasis 2008 Sept; 34(6): 502-8.

James PD, Lillicrap D.
Von Willebrand Factor.
Chapter in Mechanisms in Hematology, Core Health Services Inc, Concord Ontario, 2008.

James PD, Lillicrap D.
Molecular Diagnostic Approaches to Bleeding Disorders and Thrombophilia.
Textbook chapter for Practical Hemostasis and Thrombosis, Blackwell Science, 2005.

Peer-Reviewed Abstracts (last 5 years):

Hawke L, Poon M-C, Scully M-F, James PD.
Alterations in aberrant and endothelial splicing of von Willebrand factor under high laminar shear stress.
Accepted by ISTH Amsterdam, June 2013.

Rand M, Grabell J, Moorehead P, Deforest M, Wu J, Steele M, Klaassen R, Silva M, James PD.
Development of the Self-PBQ (Self-administered Pediatric Bleeding Questionnaire: Pre-testing and optimization.
Accepted by ISTH Amsterdam Feb 2013.

Bowman M, Casey L, Morrison L, Tuttle A, Walker I, Silva M, Jacobi P, Haberichter S, Lillicrap D, James PD.
Investigation of the contribution of VWF propeptide mutations to Type 3 VWD using in vitro cellular studies and patient-derived BOEC.
Accepted by ISTH Amsterdam, Feb 2013.

Mollah S, Rand M, Clark DS, Christopherson P, Mauer A, Montgomery RR, Zimmerman Program Investigators, Coller B, James PD.
The Merging Project: A Machine Learning Approach to Merge and Analyze Data from Four Different Bleeding Questionnaires.
Accepted by ISTH Amsterdam, Feb 2013.

Swystun L, Notley C, Sponagle K, James PD, Lillicrap D.
The endothelial lectin CLEC4M is a novel clearance receptor for Factor VIII.
Accepted ISTH Amersterdam, Feb 2013.

Albanez S, Michels A, Sponagle K, Grabell G, James PD, Lillicrap D.
An evaluation of the age-related quantitative and qualitative pathophysiology of VWF.
Accepted by ISTH Amsterdam, Feb 2013.

Moorehead P, Thibeault L, Tuttle A, Grabell J, Dwyre L, Silva M, James PD, Lillicrap D.
Rapid Immune Tolerance Induction Following Early Primary Immunologic Prophylaxis in a Hemophilia A Patient with High-Titre Inhibitor.
Accepted by ISTH Amsterdam, Feb 2013.

Swystun L, Rydz N, Notley C, Riches J, Paterson AD, Montgomery RR, James PD, Lillicrap D.
Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels.
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 16.

Rimmer E, Jamieson MA, James PD.
Rates of Malposition and Expulsion of Levonorgestrel Intrauterine System Among Women with Inherited Bleeding Disorders in a Canadian Centre.
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 3367.

Bowman M, Ling L, Pluthero F, Christensen H, Walker I, Kahr W, James PD.
Comparative Cellular Studies of the VWF Exon 4-5 Deletion Mutation Using Patient-Derived BOEC (Blood Outgrowth Endothelial Cells) and Megakaryocytes.
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 1076.

Hawke L, Scully M-F, James PD.
In Vitro and Ex Vivo Investigation of Aberrant and Alternative Splicing of von Willebrand Factor.
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 2179.

Labarque V, Blanchette V, Clark DS, James PD, Rand ML.
Prospective comparison of the pediatric bleeding questionnaire (PBQ) and ISTH-BAT in children referred to a tertiary-care pediatric centre.
Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 2229.

Demers C, James P, Winikoff R.
Hemostatic changes during pregnancy in healthy women and in women with inherited bleeding disorders.
Haemophilia 2012; 18: Suppl 3 PO-MO-266.

Deforest M, Grabell J, Tuttle A, Thibeault L, Hopman W, James P.
Generation and Optimization of the Self-Administered Bleeding Assessment Tool (Self-BAT).
Haemophilia 2012; 18: Suppl 3 FP-TU-04.3-4.

Rydz N, Leggo J, Tinlin S, James P, Lillicrap D and the AHCDC.
The Canadian “National Program for Hemophilia Mutation Testing” database: a ten-year anniversary review.
Haemophilia 2012; 18: Suppl 3 PO-MO-153.

Rydz N, Grabell J, Lillicrap D and James P.
Changes in von WIllebrand factor level and activity with age in Type 1 von Willebrand disease.
Haemophilia 2012; 18: Suppl 3 PO-MO-249.

Segbefia CI, Biss TT, Clark DS, James PD, Blanchette VS, Rand ML.
Identification of Children with Significant Epistaxis: Comparison of the Katsanis et al Epistaxis Scoring System and the Pediatric Bleeding Quesitonnaire Epistaxis Score.
ISTH Kyoto 2011 P-WE-552.

Albanez S, Grabell J, Burnett E, Sponagle K, James PD, Lillicrap D.
Increased VWF Levels in Later Life are Associated with Evidence of Both Enhanced Biosynthesis and Reduced Clearance.
ISTH Kyoto 2011 P-MO-444.

Rydz N, Boonyawat B, Riches J, Hopman W, Paterson A, Montgomery R, Lillicrap D, James PD.
Genetic variability of the CLEC4M Endothelial Lectin Receptor in Type 1 von Willebrand Disease.
ISTH Kyoto 2011 O-MO-137.

James PD, Biss TT, Clark DS, Grabell J, Riddel J, Silva M, Rapson D and Rand ML. -1 to +4 vs. 0 to +3?:
Comparing scoring systems for bleeding symptoms in the Condensed MCMDM-1 VWD and the Pediatric Bleeding Questionnaires.
ISTH Kyoto 2011 P-MO-455.

James P, Bowman M, Grabell J, Dwyre L, Rapson D.
Prospective Validation of the Condensed MCMDM1-VWD Bleeding Questionnaire for Platelet Function Disorders.
ISTH Kyoto 2011 P-WE-092.

Jackson S, Poon M-C, Grabell J, Lillicrap D and James P.
The Condensed MCMDM-1 VWD Bleeding Questionnaire: Utility as a Diagnostic Tool in the Hematology Clinic.
ISTH Kyoto 2011 P-TU-459.

Segbefia CI, Biss TT, Clark DS, James PD, Riddel J, Blanchette V, Rand M.
Evaluation of the severity and pattern of epistaxis in children with a mucocutaneous bleeding disorder and in healthy children using a standardized questionnaire. Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:713.

Holden R, Tuttle A, MacLeod F, Burbidge T, Hegadorn C and James PD.
Association of Quantitative and Qualitative Abnormalities of von Willebrand Factor and Risk of Death in Hemodialysis Patients.
Blood (ASH Annual Meeting Abstracts), Nov 2010; 116:2217.

Holme PA, James P, Gomez K, Fogarty P on behalf of the Global Emerging Hemophilia Experts Panel (GEHEP).
Variation in International Practices for the Peri-operative Management of Major Surgery for Persons with Severe Hemophilia.
Haemophilia 2010, 16 (Suppl 4), 06P21.

S. Purcell, S. Sanders, M. Silva, S. Palerme, P. James.
Implementation of a Women and Bleeding Disorders Clinic: Enhancing the Comprehensive Care Model.
Haemophilia 2010, 16 (Suppl 4), 04P26.

Walter Kahr, Fred Pluthero, Victor Blanchette, Sue Robinson, David Lillicrap, Paula D. James.
Type 3 von Willebrand disease: plasma versus platelets.
Blood 2009; Vol 114, Issue 22, Abstract 3059.

Amrit Kahlon, Julie Grabell, Angie Tuttle, Dale Engen, Wilma Hopman, David Lillicrap and Paula James.
Quantitation of Changes in VWF and FVIII Following Elective Orthopedic Surgery in Normal Individuals.
Blood 2009; Vol 114, Issue 22, Abstract 1296.

S.L. Haberichter, G. Castaman, P.D. James, P.A. Christopherson, F. Roheghiero, D. Lillicrap, R.R. Montgomery.
Clearance of von Willebrand factor (VWF) in type 2 von Willebrand disease (VWD): the implications of VWF propeptide (VWFPP) and VWF:Ag levels. J Thromb Haemost 2009; Vol 7, Suppl 2: Abstract AS-MO-017.

N. Hickson, D.J. Hampshire, P.R. Winship, P.D. James, I.R. Peake, A.C. Goodeve.
Associations between the von Willebrand factor gene (VWF) variant C.2771G > A (P.R924Q), von Willebrand factor antigen (VWF:Ag) and FVIII activity (FVIII:C) levels and its role as a risk factor for type 1 von Willebrand disease (VWD).
J Thromb Haemost 2009; Volume 7, Supplement 2: Abstract AS-MO-019.

T.T. Biss, V.S. Blanchette, D.S. Clark, C.D. Wakefield, D. Lillicrap, P.D. James, M.L. Rand.
Identification of children with significant mucocutaneous bleeding: comparison of the hospital for sick children (HSC) criteria and a quantitative pediatric-specific bleeding questionnaire (PBQ).
J Thromb Haemost 2009; Vol 7, Suppl 2: Abstract AS-TH-053.

S.L. Haberichter, P.D. James, P.A. Christopherson, D. Lillicrap, R.R. Montgomery.
Reduced VWF survival in two large cohorts of type 1 VWD patients from the Canadian type 1 VWD and us VWD (ZPMCB-VWD) studies.
J Thromb Haemost 2009; Vol 7, Suppl 2: Abstract OC-WE-133.

Robertson J, Yenson P, Rand M, Blanchette V, Lillicrap D, James P.
Expanded Phenotype-Genotype Correlations in a Paediatric Population with Type 1 VWD.
J Thromb Haemost 2009; Vol 7, Suppl 2: Abstract PP-MO-639.

Bowman M, Blanchette V, Tuttle A, AHCDC, Lillicrap D, James P.
Phenotypic and Genotypic Characterization of a Canadian Cohort of Type 3 VWD Patients.
J Thromb Haemost 2009: Vol 7, Suppl 2: Abstract PP-TH-628.

P. James, C. Hegadorn, J. Grabell, E. Ong, D. Rapson, C. AHCD, U. Budde, D. Lillicrap. Comparative analysis of von Willebrand Factor multimers from the Canadian type 1 VWD study.
J Thromb Haemost 2009; Vol 7, Suppl 2: Abstract PP-TH-639.

Bowman M, Silva M, Hopman W, Rand M, Blanchette V, Rapson D, Lillicrap D, James P. The Prevalence of Symptomatic von Willebrand Disease in a Pediatric Population.
Haemophilia May 2008. Vol 14 Issue S2, 18 PO 30.

Biss T, Blanchette V, Clark D, Wakefield C, Lillicrap D, James P, Rand M.
Use of a standardized pediatric bleeding score to quantitate bleeding symptoms in children with platelet function disorders.
Haemophilia May 2008. Vol 14 Issue S2 .

Riddel J, Bowman M, Aouizerat B, James P.
Evaluation of a standardized pediatric bleeding score in a normal population.
Haemophilia May 2008. Vol 14 Issue S2, 15 PO 13.

Biss T, Blanchette VS, Bowman M, Clark DS, Silva MP, Lillicrap D, James P, Rand M.
Quantitation of Bleeding Symptoms in Children with von Willebrand Disease (VWD) or a Platelet Function Disorder: Use of a Standardized Pediatric Bleeding Score.
Blood (ASH Annual Meeting Abstracts) Nov 16, 2007; 110: 2137.

James P, Bowman M, Tuttle A, Chirinian Y, Hopman W, Benform K, Rapson D, Lillicrap D.
The prevalence of symptomatic von Willebrand disease (VWD) in primary care practice.
J Thromb Haemost 2007; 5 Supplement 2: O-T-061. 

Rapson D, Bowman M, Lillicrap D, James P.
Diagnostic efficacy of systematic investigation of non-von Willebrand bleeders:  Results of a prospective study.
J Thromb Haemost 2007; 5 Supplement 2: P-T-217.

Othman M, Leggo J, Notley C, James P, Lillicrap D .
Platelet type von Willebrand disease: An underdiagnosed cause of excessive mucocutaneous bleeding.
J Thromb Haemost 2007; 5 Supplement 2: P-W-167.

Stakiw J, Bowman M, Hegadorn C, Pruss C, Notley C, Groot E, Lenting P, Lillicrap D, James P.
The effect of exercise on individuals with Type 1 and Type 2B von Willebrand disease (VWD).
J Thromb Haemost 2007; 5 Supplement 2: P-W-160.

Notley C, Hegadorn C, Walker I, Poon M-C, Lillicrap D, James PD
Challenges in defining type 2M von Willebrand disease: results from a Canadian Cohort Study.
J Thromb Haemost 2007; 5 Supplement 2: O-T-064.

Paula James, Members of Molecular Hemostasis Research Lab, AHCDC, David Lillicrap.
Genetic Differences Between Obligate Carriers of Type 3 von Willebrand Disease (VWD) and Individuals with Type 1 VWD: Preliminary Results from The Canadian Type 3 VWD Study.
Haemophilia 2006; 12(Suppl. 2): 30FP892.